GlassScriptPhysician profile
Thomas James Sisk
NPI 1538783139
$933.90
in general payments reported to CMS, 2019-2025
15 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $680 · 2022: $143 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $231.65 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $144.51 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.66 | 2021-2022 | |
| Glaxosmithkline, LLC. | $88.48 | 2021-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.36 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.58 | 2021-2022 | |
| Novo Nordisk INC | $65.57 | 2021 | |
| Lilly USA, LLC | $29.08 | 2021 | |
| Pulmonx Corporation | $28.37 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Alkermes, INC. | $27.42 | 2025 | Vivitrol |
| Merck Sharp & Dohme LLC | $27.13 | 2025 | Capvaxive, Gardasil 9 |
| Esperion Therapeutics, INC. | $14.76 | 2021 | |
| Irhythm Technologies, INC. | $12.82 | 2021 | |
| Insmed, INC. | $12.06 | 2021 | |
| Genentech USA, INC. | $4.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sisk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.